Cefamandole Nafate Free Base

CHEMBL1201218 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
490.5 g/mol
LogP
-0.3
Phase
4

The free base form of cefamandole nafate is a parenteral second-generation cephalosporin prodrug converted to active cefamandole in the body. It is used for treating susceptible gram-positive and gram-negative bacterial infections. Caution is warranted regarding its interaction with alcohol and potential effects on vitamin K-dependent clotting factors.

Молекулярная масса

490,5000 g/mol

LogP

-0,30

TPSA

207,00 Ų

Правило пяти Липинского

Соответствует

Механизм действия

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1

InChI

InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1

Molecular Formula

C19H18N6O6S2

HBD / HBA

2 / 11

Вращаемые Связи

9

Тяжёлые Атомы

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

The free base form of cefamandole nafate is a parenteral second-generation cephalosporin prodrug converted to active cefamandole in the body. It is used for treating susceptible gram-positive and gram-negative bacterial infections. Caution is warranted regarding its interaction with alcohol and potential effects on vitamin K-dependent clotting factors.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefamandole Nafate Free Base is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201218. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5284527. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.